Loading...
•
Mar 31, 2020
Regulus Therapeutics Q1 2020 Earnings Report
Reported financial results for the first quarter ended March 31, 2020, and provided a corporate update.
Key Takeaways
Regulus Therapeutics reported its Q1 2020 financial results, with a net loss of $5.9 million, or $0.25 per share, and cash and cash equivalents of $28.1 million. The company initiated dosing of the third and final cohort in the Phase 1 multiple ascending dose clinical study for RGLS4326.
Initiated dosing of the third and final cohort in RGLS4326 Phase 1 for ADPKD in April 2020.
Planning to initiate a Phase 1b short-term dosing study in patients with ADPKD in the second half of 2020.
Cash and cash equivalents totaled $28.1 million as of March 31, 2020.
Net loss was $5.9 million, or $0.25 per share, for the first quarter of 2020.
Forward Guidance
The company expects to complete the Phase 1 MAD study in mid-2020 and plans to initiate a Phase 1b study in the second half of 2020.
Positive Outlook
- Completion of the second cohort in the Phase 1 multiple ascending dose clinical study for RGLS4326.
- Initiation of dosing for the third and final cohort in the Phase 1 MAD clinical study for RGLS4326.
- Preparations for the Phase 1b study in patients with autosomal dominant polycystic kidney disease are well underway.
- Expectation to complete the Phase 1 MAD study in mid-2020 with topline results available thereafter.
- Planning to initiate a Phase 1b short-term dosing study in patients with ADPKD in the second half of 2020.
Challenges Ahead
- The COVID-19 pandemic is expected to adversely affect business operations and financial results.
- The extent of the impact on Regulus’ ability to achieve its preclinical and clinical development objectives is uncertain.
- The value of and market for its common stock will depend on future developments that are highly uncertain.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...